Abstract 767P
Background
Cisplatin-based concurrent chemoradiation therapy (CCRT) has been increasingly used for local advanced cervical cancer (LACC). However, recurrence is common after cisplatin-based CCRT. Several treatment strategies have been explored to further improve the outcome. We aimed to evaluate the safety and efficacy of anti-PD-1 (Toripalimab, a humanized immunoglobulin G monoclonal antibody against programmed death 1) combined with cisplatin-based concurrent IMRT for locally advanced cervical cancer.
Methods
This is an open-label, nonrandomized, prospective phase Ⅰ/II study in a single arm. Patients with untreated LACC (2018 FIGO stage IB3, IIA –IVA) were enrolled. All patients were treated with CCRT for 56 days including cisplatin (40 mg/m2, Q1W) combined with image-guidance volume modulated Arc therapy (IG-VMAT) to pelvis (50.4Gy in 28 fractions, pelvic and paraortic nodes with simultaneous nodal boost to 59.4 Gy, 28 fractions), and followed by HDR intracavitary (30-36 Gy in 5-6 fractions) brachytherapy. Toripalimab was administered intravenously at 240 mg every 2 week for 4 cycles. The primary endpoint was incidence and severity of acute adverse events up to 3 months of completing treatment. The secondary endpoints were ORR and PFS.
Results
From Sep 2020 to Sep 2022, a total of 30 patients were enrolled. Median age was 58 years [range: 23–71]. The median follow-up duration was 8.5 months [range: 3.2–27.3]. 29 patients (29/30, 96.7%) completed the treatment, 1 patient (1/30, 3.3%) terminated the treatment because of hemophagic syndrome, who with a history of liver fluke disease. ORR was 100.0% (30/30) at 3 months after treatment. Treatment-related grade 3 or 4 adverse events occurred in 80% (24/30) of patients, primarily leukopenia (63.3%), lymphopenia (36.7%), anemia (26.7%), neutropenia (16.7%). The grade 1-2 potentially immune-related adverse events were chromatosis 5 (16.7%), rash 2 (6.7%), pruritus 2 (6.7%), hypothyroidism 2 (6.7%), adrenal insufficiency 2 (6.7%), No treatment-related deaths occurred.
Conclusions
Toripalimab combined with cisplatin-based concurrent IMRT was tolerable and showed promising antitumor activity in patients with LACC, while immunotherapy-related toxicities should be carefully managed.
Clinical trial identification
NCT04368273.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Shanghai Junshi Biomedicine Technology Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11